Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 28, 2023

Bas Trietsch Discusses Successes so Far Using Organ on a Chip Technology for Bio/Pharmaceuticals (INTERPHEX 2023)

Bas Trietsch, chief technology officer, MIMETAS, discusses the successes he's encountered so far using organ on a chip technology in bio/pharmaceutical research.

Bas Trietsch, chief technology officer, MIMETAS, and one of the INTERPHEX Keynote speakers in the Organ on a Chip for Pharmaceutical Development session, discusses the successes his company has encountered so far using organ on a chip technology in bio/pharmaceutical research.

For more INTERPHEX 2023 video content, check this page for updates.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.